Andrew Hughes
Director/Board Member at CellCentric Ltd.
Network origin in Andrew Hughes first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 9 | |
CellCentric Ltd.
 CellCentric Ltd. Pharmaceuticals: MajorHealth Technology CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Andrew Hughes via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Bioenvision, Inc.
 Bioenvision, Inc. Medical/Nursing ServicesHealth Services Bioenvision, Inc. engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer. It also develops anti-infective technologies, which includes the OLIGON(R) technology. The company was founded by Christopher B. Wood on August 16, 1996 and is headquartered in New York, NY. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
Piramed Ltd.
 Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| PROBI AB | Biotechnology | Director/Board Member | |
Copenhagen Capacity
 Copenhagen Capacity Financial ConglomeratesFinance Copenhagen Capacity provides investment promotion and economic development services. The private company is based in Copenhagen, Denmark. Asbjørn Overgaard Christiansen has been the CEO of the Danish company since 2020. | Financial Conglomerates | Director/Board Member | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| MEDIVIR AB | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Karolinska Institutet | College/University | Doctorate Degree | |
| University of Stockholm | College/University | Masters Business Admin | |
| CALLIDITAS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member | |
| University of Turku | College/University | Doctorate Degree | |
| WEIFA ASA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Royal Institute of Technology | College/University | Doctorate Degree | |
| University of Oslo | College/University | Doctorate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree | |
| École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin | |
| University of Strasbourg | College/University | Graduate Degree | |
| University of Lyon | College/University | Doctorate Degree | |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The private company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| OSI Pharmaceuticals (UK) Ltd. | Corporate Officer/Principal | ||
| Baxter Medical AB | Corporate Officer/Principal | ||
| BERGENBIO ASA | Pharmaceuticals: Major | Chairman | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| ADVICENNE | Pharmaceuticals: Generic | Corporate Officer/Principal | |
Oslo universitetssykehus HF
 Oslo universitetssykehus HF Hospital/Nursing ManagementHealth Services Oslo universitetssykehus HF operates local hospital, acute hospitals, and regional hospital for residents and has a number of national tasks. It carries out patient treatment, research, and trial treatments, gives advice and provides education. The company was founded on December 1, 2008 and is headquartered in Oslo, Norway. | Hospital/Nursing Management | Corporate Officer/Principal | |
Immedica Pharma AB
 Immedica Pharma AB Medical DistributorsDistribution Services Immedica Pharma AB provides know-how and access of specialty care medicine and products. It also provides information on regulatory and medical affairs and product distribution. The company is headquartered in Stockholm, Sweden. | Medical Distributors | Chief Tech/Sci/R&D Officer | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chief Executive Officer | |
| Institut de Pharmacie Industrielle de Lyon | College/University | Graduate Degree | |
| KLARIA PHARMA HOLDING AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| IDOGEN AB (PUBL) | Biotechnology | Chief Executive Officer | |
| HERANTIS PHARMA OYJ | Pharmaceuticals: Major | Director/Board Member | |
| COMBIGENE AB | Pharmaceuticals: Major | Director/Board Member | |
Blueprint Genetics Oy
 Blueprint Genetics Oy BiotechnologyHealth Technology Blueprint Genetics Oy engages in the provision of genetic diagnostics and clinical interpretation of hereditary diseases. It offer dignistic tests for cardiology; dermatology; endocrinology; immunology; metabolic disorder; nephrology; and pulmonology. The company was founded by Tommi Pietari Lehtonen, Juha Koskenvuo, Tero-Pekka Alastalo, and Samuel Myllykangas in 2008 and is headquartered in Helsinki, Finland. | Biotechnology | Chairman | |
| SEDANA MEDICAL AB | Medical Specialties | Director/Board Member | |
| Medivir Personal AB | Corporate Officer/Principal | ||
| EXACT THERAPEUTICS | Biotechnology | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| ZICCUM AB | Medical Specialties | Director/Board Member | |
Pluvia AS
 Pluvia AS Miscellaneous Commercial ServicesCommercial Services Pluvia AS operates as a research-based pharmaceutical company. The company is headquartered in Bergen, Norway. | Miscellaneous Commercial Services | Director/Board Member | |
Bio-Me AS
 Bio-Me AS BiotechnologyHealth Technology Bio-Me AS operates as a boi-tech firm. It researches and develops patented technologies and new approaches in bacteria analysis. The company is headquartered in Oslo, Norway. | Biotechnology | Director/Board Member | |
J&J Future Invest AS
 J&J Future Invest AS Real Estate DevelopmentFinance J & J Future Invest AS is a Norwegian company that operates a real estate agency. | Real Estate Development | Corporate Officer/Principal | |
| Herder Consulting AB | Director/Board Member | ||
| Tappin AS | Director/Board Member | ||
| Glycovisc BioTech AB | Corporate Officer/Principal | ||
| ONCOZENGE AB | Pharmaceuticals: Major | Director/Board Member | |
| ELICERA THERAPEUTICS AB | Biotechnology | Director/Board Member |
Statistics
International
| Sweden | 24 |
| Norway | 12 |
| France | 6 |
| United Kingdom | 4 |
| Finland | 4 |
Sectoral
| Health Technology | 28 |
| Consumer Services | 10 |
| Commercial Services | 4 |
| Health Services | 3 |
| Finance | 3 |
Operational
| Director/Board Member | 49 |
| Corporate Officer/Principal | 27 |
| Independent Dir/Board Member | 14 |
| Chief Tech/Sci/R&D Officer | 13 |
| Doctorate Degree | 10 |
Most connected contacts
| Insiders | |
|---|---|
| Hilde Hermansen Steineger | 24 |
| Hilde Furberg | 21 |
| Christina Elisabeth Herder | 15 |
| Kjetil Taskén | 11 |
| William West | 10 |
| Neil Pegg | 7 |
| Andrew Saunders | 6 |
| Ludovic Robin | 6 |
| Hans Olivecrona | 5 |
| Per Walday | 4 |
| Amir Snapir | 4 |
| Gael L'Hévéder | 2 |
- Stock Market
- Insiders
- Andrew Hughes
- Company connections